The BSIM2 team is pairing the application of state-of-the-art molecular modelling and cheminformatics tools with its extensive knowledge in medicinal chemistry and pharmaceutical technology to bring novel therapies for neurodegenerative diseases to light.




BSIM2 is strategically committed to utilising computer-based technologies to develop high-quality molecules for the treatment of challenging diseases. AMILOTERA is the company's most advanced discovery programme and targets transthyretin-related amyloid diseases: Familial Amyloidotic Polyneuropathy (FAP) and Familial Amyloidotic Cardiomyopathy (FAC). The company embraces the truly complex and multi-dimensional nature of drug discovery and development by combining a myriad of computational workflows for compound screening and optimisation, heavily reducing the number of molecules that need to be experimentally assayed and the associated risks of attrition.


For more information on BSIM2’s portfolio of products or discussing potential partnering opportunities, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.